These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30900800)

  • 41. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.
    Creary SE; Beeman C; Stanek J; King K; McGann PT; O'Brien SH; Liem RI; Holl J; Badawy SM
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29607. PubMed ID: 35373884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment adherence in patients with sickle cell anemia.
    Drotar D
    J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
    [No Abstract]   [Full Text] [Related]  

  • 44. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
    Nottage KA; Ware RE; Winter B; Smeltzer M; Wang WC; Hankins JS; Dertinger SD; Shulkin B; Aygun B
    Eur J Haematol; 2014 Nov; 93(5):377-83. PubMed ID: 24796940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
    McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
    Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
    Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
    J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydroxyurea marketed for sickle cell anemia.
    Am J Health Syst Pharm; 1998 May; 55(9):875. PubMed ID: 9588244
    [No Abstract]   [Full Text] [Related]  

  • 49. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
    Strouse JJ; Heeney MM
    Pediatr Blood Cancer; 2012 Aug; 59(2):365-71. PubMed ID: 22517797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High hydroxyurea usage in sickle cell anemia regardless of patient demographics.
    Phan V; Park JA; Dulman R; Lewis A; Briere N; Notarangelo B; Yang E
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30728. PubMed ID: 38069808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
    Olujohungbe A; Cinkotai KI; Yardumian A
    BMJ; 1998 Jun; 316(7146):1689. PubMed ID: 9614013
    [No Abstract]   [Full Text] [Related]  

  • 52. Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia.
    Crosby LE; Shook LM; Ware RE; Brinkman WB
    Pediatr Blood Cancer; 2015 Feb; 62(2):184-185. PubMed ID: 25308571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 54. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
    Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
    Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
    Wang WC; Helms RW; Lynn HS; Redding-Lallinger R; Gee BE; Ohene-Frempong K; Smith-Whitley K; Waclawiw MA; Vichinsky EP; Styles LA; Ware RE; Kinney TR
    J Pediatr; 2002 Feb; 140(2):225-9. PubMed ID: 11865275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How I use hydroxyurea to treat young patients with sickle cell anemia.
    Ware RE
    Blood; 2010 Jul; 115(26):5300-11. PubMed ID: 20223921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B; Yousefi H; Bahadoram M
    Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 60. Medical Neglect by Underprescription and Underutilization of Hydroxyurea in Children with Sickle Cell Disease.
    Rana S
    South Med J; 2016 Sep; 109(9):503-5. PubMed ID: 27598349
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.